Abstract

In 2021, the WHO revised its classification of central nervous system (CNS) tumors, which has resulted in changes to both the diagnostic and treatment landscapes. At the NCCN 2023 Annual Conference, this tumor board–style presentation featured 4 case studies to demonstrate an evidence-based approach to the treatment of patients with various WHO-defined types of diffuse glioma. The NCCN Guidelines have been updated to reflect the WHO reclassification of CNS tumors and provide treatment recommendations accordingly.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call